Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Total Non-Current Liabilities data on record, last reported at $345.0 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 3.55% year-over-year to $345.0 million; the TTM value through Dec 2025 reached $345.0 million, up 3.55%, while the annual FY2025 figure was $345.0 million, 3.55% up from the prior year.
  • Total Non-Current Liabilities reached $345.0 million in Q4 2025 per SNDX's latest filing, up from $322.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $345.0 million in Q4 2025 and bottomed at $2000.0 in Q3 2024.
  • Average Total Non-Current Liabilities over 5 years is $88.8 million, with a median of $12.7 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 99.77% in 2024, then surged 16108650.0% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $20.6 million in 2021, then tumbled by 96.5% to $722000.0 in 2022, then fell by 18.56% to $588000.0 in 2023, then skyrocketed by 56556.97% to $333.1 million in 2024, then increased by 3.55% to $345.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $345.0 million in Q4 2025, $322.2 million in Q3 2025, and $325.7 million in Q2 2025.